Vyne Therapeutics Inc. (VYNE) — 8-K Filings

8-K Filings (11)

• VYNE Therapeutics Reports Material Agreements & Executive Changes — Dec 17, 2025 Risk: medium
  VYNE Therapeutics Inc. filed an 8-K on December 17, 2025, reporting on several key events. These include entering into a material definitive agreement, unregist
• 8-K Filing — Dec 12, 2025
• VYNE Therapeutics Faces Delisting Concerns — Sep 12, 2025 Risk: high
  VYNE Therapeutics Inc. filed an 8-K on September 12, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and a tra
• VYNE Therapeutics Files 8-K on Financials and Personnel — Aug 14, 2025 Risk: medium
  VYNE Therapeutics Inc. filed an 8-K on August 14, 2025, reporting on results of operations and financial condition, director/officer changes, and financial stat
• VYNE Therapeutics Files 8-K on Operations and Events — Jul 30, 2025 Risk: low
  VYNE Therapeutics Inc. filed an 8-K on July 30, 2025, reporting on its results of operations and financial condition, as well as other events and financial stat
• VYNE Therapeutics Files 8-K: Other Events & Exhibits — Jan 13, 2025 Risk: low
  On January 13, 2025, VYNE Therapeutics Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicatin
• VYNE Therapeutics Files 8-K — Dec 23, 2024 Risk: low
  VYNE Therapeutics Inc. filed an 8-K on December 23, 2024, reporting other events and financial statements. The company, formerly known as Menlo Therapeutics Inc
• VYNE Therapeutics Appoints New CEO, Files 8-K — Dec 12, 2024 Risk: medium
  VYNE Therapeutics Inc. announced on December 12, 2024, the appointment of Dr. Paul R. Edick as Chief Executive Officer and a member of the Board of Directors. D
• VYNE Therapeutics Files 8-K — Sep 12, 2024 Risk: low
  VYNE Therapeutics Inc. filed an 8-K on September 12, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specifi
• VYNE Therapeutics Files 8-K on Financial Condition — Feb 29, 2024 Risk: medium
  VYNE Therapeutics Inc. filed an 8-K on February 29, 2024, reporting on its results of operations and financial condition. The filing indicates that the company,
• VYNE Therapeutics Reports Officer/Director Changes, Comp Arrangements — Jan 3, 2024
  VYNE Therapeutics Inc. filed an 8-K on January 3, 2024, reporting an event that occurred on December 29, 2023. The filing indicates a change in directors or off

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX